Krebs Biochemicals Reports Significant Financial Challenges in March 2025 Results
Krebs Biochemicals & Industries has reported challenging financial results for the quarter ending March 2025, with a significant decline in net sales and profitability. Key metrics, including a negative operating profit margin and earnings per share, indicate ongoing difficulties and suggest a need for strategic reassessment within the company.
Krebs Biochemicals & Industries has recently reported its financial results for the quarter ending March 2025, revealing significant challenges within the company. The evaluation changes indicate a notable decline in the stock's score, which has shifted to a lower position compared to the previous three months.The financial data highlights a substantial drop in net sales, recorded at Rs 6.10 crore, reflecting a year-on-year decrease of 49.04%. This trend suggests ongoing difficulties in generating revenue. Additionally, the profit before tax less other income (PBT) stands at Rs -8.59 crore, marking a year-on-year decline of 41.75%. This indicates a concerning trend in the company's profitability.
Krebs Biochem's operating profit margin has also reached its lowest point in five quarters at -88.69%, signaling challenges in operational efficiency. Furthermore, the earnings per share (EPS) have fallen to Rs -3.84, underscoring a decline in profitability and lower returns for shareholders.
Overall, the financial results for Krebs Biochemicals & Industries reflect a challenging environment, with various metrics indicating a need for strategic reassessment.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
